SOUTH SAN FRANCISCO, Calif. — August 20, 2025 — Leads & Copy — Cytokinetics, Incorporated (Nasdaq: CYTK) has announced the appointment of James M. Daly to its Board of Directors, effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience to the role, with expertise in commercialization.
Robert I. Blum, Cytokinetics’ President and Chief Executive Officer, stated that Mr. Daly’s expertise in leading commercial launches of innovative therapies and his extensive board experience will be valuable as the company advances toward becoming a fully integrated commercial organization.
Most recently, Mr. Daly served as the Chief Commercial Officer at Incyte Corporation, where he led the launch of Jakafi® (ruxolitinib). He previously spent 10 years at Amgen in senior leadership positions and launched medicines including Neulasta®, Xgeva®, Nplate® and Vectibix®. He began his career at GlaxoSmithKline. Mr. Daly earned a B.S. in Pharmacy and an M.B.A. from the University at Buffalo, SUNY. He currently serves on the Boards of Madrigal Pharmaceuticals, argenx SE, and Acadia Pharmaceuticals.
Cytokinetics is a specialty cardiovascular biopharmaceutical company advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. The company is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor. Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
Contact: Diane Weiser, Senior Vice President, Corporate Affairs, (415) 290-7757
Source: Cytokinetics
